GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Modalis Therapeutics Corp (TSE:4883) » Definitions » EV-to-FCF

Modalis Therapeutics (TSE:4883) EV-to-FCF : (As of May. 18, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Modalis Therapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Modalis Therapeutics's Enterprise Value is 円683.24 Mil. Modalis Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was 円0.00 Mil. Therefore, Modalis Therapeutics's EV-to-FCF for today is .

The historical rank and industry rank for Modalis Therapeutics's EV-to-FCF or its related term are showing as below:

TSE:4883' s EV-to-FCF Range Over the Past 10 Years
Min: -29.49   Med: 0   Max: 0
Current: -0.3

TSE:4883's EV-to-FCF is ranked worse than
100% of 520 companies
in the Drug Manufacturers industry
Industry Median: 24.215 vs TSE:4883: -0.30

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-18), Modalis Therapeutics's stock price is 円63.00. Modalis Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was 円-77.240. Therefore, Modalis Therapeutics's PE Ratio for today is At Loss.


Modalis Therapeutics EV-to-FCF Historical Data

The historical data trend for Modalis Therapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Modalis Therapeutics EV-to-FCF Chart

Modalis Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial - -47.78 -15.00 -3.30 -1.16

Modalis Therapeutics Quarterly Data
Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.30 - - - -1.16

Competitive Comparison of Modalis Therapeutics's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Modalis Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Modalis Therapeutics's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Modalis Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Modalis Therapeutics's EV-to-FCF falls into.



Modalis Therapeutics EV-to-FCF Calculation

Modalis Therapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=683.244/0
=

Modalis Therapeutics's current Enterprise Value is 円683.24 Mil.
Modalis Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Modalis Therapeutics  (TSE:4883) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Modalis Therapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=63.00/-77.240
=At Loss

Modalis Therapeutics's share price for today is 円63.00.
Modalis Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-77.240.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Modalis Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Modalis Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Modalis Therapeutics (TSE:4883) Business Description

Traded in Other Exchanges
N/A
Address
16-5 Nihombashi-Kabuto-cho, Chuo-ku, Tokyo, JPN, 103-0026
Modalis Therapeutics Corp is a drug development company. It is engaged in research and development of Gene Therapy using core platform technology, non-editing CRISPR technology (CRISPR-GNDM). The company's products in pipeline are MDL-201, MDL-202, MDL-204, MDL-205, MDL-206, MDL-101, and MDL-102.

Modalis Therapeutics (TSE:4883) Headlines

No Headlines